SCYX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
SCYNEXIS (SCYX) is not a good buy right now for an impatient investor. There are no proprietary buy signals, no fresh news catalyst, revenue is contracting sharply, and the chart is sitting below the pivot with weakening momentum. This is better treated as a high-risk watchlist name until it either reclaims ~0.75 and holds, or cleanly bounces off ~0.66 support with improving momentum.
Price/Trend: SCYX is down -3.92% to 0.7293, trading below the pivot (0.748), which keeps the near-term bias slightly bearish-to-neutral. Momentum: MACD histogram is positive (0.00612) but positively contracting, implying upside momentum is fading rather than accelerating. RSI(6)=43.15 is neutral but slightly weak (not oversold), so there is no strong “snap-back” signal yet. Moving Averages: Converging moving averages suggest consolidation/indecision rather than a confirmed trend. Levels: Immediate resistance is the pivot at 0.748, then R1 at 0.836. Key supports are S1 at 0.659 and S2 at 0.604. A breakdown below ~0.659 would materially worsen the setup; a reclaim/hold above ~0.748 would improve it. Pattern-based odds: The provided analog-pattern model implies a modest bullish drift (60% chance) with projected +2.28% next day and ~+8% over week/month, but it is not corroborated by a strong momentum breakout today.
Intellectia Proprietary Trading Signals
Potential technical mean-reversion if price holds the S1 support zone (~0.
and reclaims the pivot (~0.748).
Options positioning is heavily call-skewed (put OI effectively zero), which can reflect bullish bias.
Pattern-analog model suggests a modest positive drift over the next week/month (~+8%).
No news in the recent week: lack of identifiable near-term catalyst to force a breakout.
Price is below the pivot (0.
and momentum is weakening (MACD positive but contracting), which reduces the quality of a “buy now” entry.
Extremely high implied volatility (298%) versus historical (37%) implies the market is pricing major uncertainty; this often coincides with unstable price action.
Fundamental top-line trend is negative (sharp YoY revenue decline), which can keep pressure on micro/small-cap biotech names.
Latest quarter: 2025/Q3. Revenue fell to $334K (-49.39% YoY), signaling material top-line weakness. Net income was -$8.59M (still a loss; YoY comparison improved due to prior-period base effects), and EPS was -$0.17 (less negative YoY). Gross margin is reported at 100% (typical for licensing/low-COGS revenue mixes), but the key issue is scale: revenue is very small relative to ongoing losses. Overall: improving loss metrics vs prior year, but growth is not healthy and the business remains loss-making.
No analyst rating trend or price target change data was provided in the dataset, so a current Wall Street consensus shift cannot be confirmed here. Based on the available information alone, the practical pro view would focus on optionality/event-driven upside typical of biotech and the call-skew in OI; the con view would focus on collapsing revenue, ongoing losses, and the absence of a near-term catalyst.
